Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALGeneric

KERYDIN

TAVABOROLE

Standard Dose
5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview KERYDIN is listed in Drugs@FDA under application 204427 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient TAVABOROLE Form and strength SOLUTION;TOPICAL - 5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ANACOR PHARMS INC Submission history Latest submission status date: 2018-07-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview KERYDIN is listed in Drugs@FDA under application 204427 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient TAVABOROLE Form and strength SOLUTION;TOPICAL - 5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ANACOR PHARMS INC Submission history Latest submission status date: 2018-07-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.